PVAS and SCORFAD improved by ⩾50% in 61% and 88% of cats, respectively
The aim of this study was to assess the efficacy of a new therapeutic regimen of oclacitinib for the control of feline atopic skin syndrome (FASS) and to correlate plasma levels of this drug with...
